Literature DB >> 30604211

Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.

Zhenzhen Ma1, Ruohan Yu1, Jinxia Zhao1, Lin Sun1, Leilei Jian1, Changhong Li2, Xiangyuan Liu3.   

Abstract

BACKGROUND: Osteoclasts are responsible for the bone loss in rheumatoid arthritis (RA). Hypoxia has been suggested to play key roles in pathological bone loss. However, the current understanding of the effects of hypoxia on osteoclastogenesis is controversial. Effects of hypoxia on both the formation and function of osteoclasts requires examination. In the current study, we aimed to explore the effect of hypoxia on osteoclast differentiation and the underlying mechanisms.
METHODS: RAW264.7 cells and murine bone-marrow-derived monocytes were used to induce osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand (RANKL). Hypoxic conditions were maintained in a hypoxic chamber at 5% CO2 and 1% O2, balanced with N2. Osteoclasts were detected by tartrate-resistant acid phosphatase (TRAP) staining. A bone resorption assay was carried out in vitro using bone slices. RT-PCR was conducted to detect osteoclast markers and transcription factors. The phosphorylation of nuclear factor-κBα (IκBα), c-Jun N-terminal kinase (JNK), extracellular regulated protein kinase (ERK), and p38 was detected by western blotting. Mann-Whitney U test or Student's t test was used to compare differences between the two groups.
RESULTS: TRAP staining and the bone resorption assay revealed that hypoxia-restrained osteoclast differentiation and bone resorption. Expression of osteoclast markers including cathepsin K, RANK, and TRAP decreased during osteoclast differentiation under hypoxic conditions (all P < 0.05). Hypoxia at 1% O2 did not affect cell viability, whereas it dramatically abated RANKL-dependent phosphorylation of the JNK-mitogen-activated protein kinases (MAPK) and IκBα pathways. Moreover, the expression of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) was inhibited under hypoxic conditions (all P < 0.05).
CONCLUSIONS: These results suggest that constant hypoxia at 1% O2 significantly restrains osteoclast formation and resorbing function without affecting cell viability. Constant hypoxia might inhibit RANKL-induced osteoclastogenesis by regulating NFATc1 expression via interfering the phosphorylation of JNK and IκBα.

Entities:  

Keywords:  Hypoxia; JNK-mitogen-activated protein kinases; NFATC transcription factors; Osteoclast; Osteoclastogenesis

Mesh:

Substances:

Year:  2019        PMID: 30604211     DOI: 10.1007/s00011-018-1209-9

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  4 in total

1.  The Adenosine A2B Receptor Drives Osteoclast-Mediated Bone Resorption in Hypoxic Microenvironments.

Authors:  Helen J Knowles
Journal:  Cells       Date:  2019-06-21       Impact factor: 6.600

2.  Effects of rosuvastatin and zoledronic acid in combination on the recovery of senile osteoporotic vertebral compression fracture following percutaneous vertebroplasty.

Authors:  Hong Li; Yu Wang; Rui Wang; Lei Yue; Shunlun Chen; Chunde Li
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

3.  Effects of normobaric cyclic hypoxia exposure on mesenchymal stem-cell differentiation-pilot study on bone parameters in elderly.

Authors:  Marta Camacho-Cardenosa; José Manuel Quesada-Gómez; Alba Camacho-Cardenosa; Alejo Leal; Gabriel Dorado; Bárbara Torrecillas-Baena; Antonio Casado-Díaz
Journal:  World J Stem Cells       Date:  2020-12-26       Impact factor: 5.326

4.  Inhibition of Lipopolysaccharide-Induced Inflammatory Bone Loss by Saikosaponin D is Associated with Regulation of the RANKL/RANK Pathway.

Authors:  Xinhui Wu; Kangxian Zhao; Xiaoxin Fang; Feng Lu; Weikang Zhang; Xiaoting Song; Lihua Chen; Jiacheng Sun; Haixiao Chen
Journal:  Drug Des Devel Ther       Date:  2021-11-23       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.